Mixed connective tissue disease secondary prevention: Difference between revisions
(Created page with "__NOTOC__ {{Mixed connective tissue disease}} {{CMG}}; {{AE}} {{SHH}} ==Overview== There are no established measures for the secondary prevention of [disease name]. OR Effe...") |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
In MCTD effective measures for the [[Prevention (medical)|secondary prevention]] of [[Raynaud's disease]] include [[vasodilator]] therapies (such as [[Calcium channel blocker|calcium channel blockers]]), preventive measures like avoidance of cold temperatures and other triggering factors (such as [[smoking]] and [[Sympathomimetic drug|sympathomimetic agents]]) and use of warm and protection techniques of fingers. Current strategies include [[Bosentan]] ([[endothelin receptor antagonist]]) as the recommended [[medication]] for the [[Prevention (medical)|prevention]] of new digital ulcers. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
* | * In MCTD effective measures for the [[Prevention (medical)|secondary prevention]] of [[Raynaud's disease]] include:<ref name="pmid22424193">{{cite journal |vauthors=Ortega-Hernandez OD, Shoenfeld Y |title=Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment |journal=Best Pract Res Clin Rheumatol |volume=26 |issue=1 |pages=61–72 |date=February 2012 |pmid=22424193 |doi=10.1016/j.berh.2012.01.009 |url=}}</ref> | ||
** [[Vasodilator]] therapies (such as [[Calcium channel blocker|calcium channel blockers]]) | |||
** Preventive measures like avoidance of cold temperatures and other triggering factors (such as [[smoking]] and [[Sympathomimetic drug|sympathomimetic agents]]) | |||
**[ | ** Use of warm and protection techniques of fingers | ||
**[ | * Current strategies include [[Bosentan]] ([[endothelin receptor antagonist]]) as the recommended [[medication]] for the [[Prevention (medical)|prevention]] of new digital ulcers. | ||
**[ | |||
==References== | ==References== | ||
Revision as of 21:14, 19 April 2018
|
Mixed connective tissue disease Microchapters |
|
Differentiating Mixed connective tissue disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Mixed connective tissue disease secondary prevention On the Web |
|
American Roentgen Ray Society Images of Mixed connective tissue disease secondary prevention |
|
Mixed connective tissue disease secondary prevention in the news |
|
Blogs onMixed connective tissue disease secondary prevention |
|
Directions to Hospitals Treating Mixed connective tissue disease |
|
Risk calculators and risk factors for Mixed connective tissue disease secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
In MCTD effective measures for the secondary prevention of Raynaud's disease include vasodilator therapies (such as calcium channel blockers), preventive measures like avoidance of cold temperatures and other triggering factors (such as smoking and sympathomimetic agents) and use of warm and protection techniques of fingers. Current strategies include Bosentan (endothelin receptor antagonist) as the recommended medication for the prevention of new digital ulcers.
Secondary Prevention
- In MCTD effective measures for the secondary prevention of Raynaud's disease include:[1]
- Vasodilator therapies (such as calcium channel blockers)
- Preventive measures like avoidance of cold temperatures and other triggering factors (such as smoking and sympathomimetic agents)
- Use of warm and protection techniques of fingers
- Current strategies include Bosentan (endothelin receptor antagonist) as the recommended medication for the prevention of new digital ulcers.
References
- ↑ Ortega-Hernandez OD, Shoenfeld Y (February 2012). "Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment". Best Pract Res Clin Rheumatol. 26 (1): 61–72. doi:10.1016/j.berh.2012.01.009. PMID 22424193.